TRI 102

Drug Profile

TRI 102

Alternative Names: TRI-102; TRI102-ADD-001

Latest Information Update: 17 Jul 2015

Price : $50

At a glance

  • Originator Tris Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Clinical Phase Unknown Diabetes mellitus

Most Recent Events

  • 16 May 2014 Clinical trials in Diabetes mellitus in USA (unspecified route)
  • 01 Mar 2014 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top